

# Journal of Thoracic Oncology

## Small Cell Lung Cancer Articles Published in 2020 and 2021

[Overcoming Chemotherapy Resistance in SCLC](#) by Herzog, Brett H. et al.  
Journal of Thoracic Oncology, in press

[Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers](#) by Qu, Song et al. Journal of Thoracic Oncology, in press

[Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study](#) by Blackhall, Fiona et al.  
Journal of Thoracic Oncology, Volume 16, Issue 9, 1547 – 1558

[A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC](#) by Malhotra, Jyoti et al.  
Journal of Thoracic Oncology, Volume 16, Issue 9, 1559 – 1569

[Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study](#) by Johnson, Melissa L. et al. Journal of Thoracic Oncology, Volume 16, Issue 9, 1570 – 1581

[Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study](#) by Ai, Xinghao et al. Journal of Thoracic Oncology, Volume 16, Issue 8, 1403 – 1414

[Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC](#) by Thomas, Portia L. et al. Journal of Thoracic Oncology, Volume 16, Issue 7, 1211 – 1223

[YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype](#) by Owonikoko, Taofeek K. et al. Journal of Thoracic Oncology, Volume 16, Issue 3, 464 – 476

[Camrelizumab Plus Apatinib in Extensive-Stage SCLC \(PASSION\): A Multicenter, Two-Stage, Phase 2 Trial](#) by Fan, Yun et al. Journal of Thoracic Oncology, Volume 16, Issue 2, 299 – 309

[American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020](#) by Chun, Stephen G. et al. Journal of Thoracic Oncology, Volume 16, Issue 1, 66 – 75

[American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC](#) by Higgins, Kristin A. et al. Journal of Thoracic Oncology, Volume 16, Issue 1, 54 – 65

[SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization](#) by Baine, Marina K et al. Journal of Thoracic Oncology, Volume 15, Issue 12, 1823 – 1835

[Role of mTOR As an Essential Kinase in SCLC](#) by Kern, Jeffrey A. et al. Journal of Thoracic Oncology, Volume 15, Issue 9, 1522 – 1534

[Harnessing Natural Killer Immunity in Metastatic SCLC](#) by Best, Sarah A. et al. Journal of Thoracic Oncology, Volume 15, Issue 9, 1507 – 1521

[New Approaches to SCLC Therapy: From the Laboratory to the Clinic](#) by Poirier, John T. et al. Journal of Thoracic Oncology, Volume 15, Issue 4, 520 – 540



## Small Cell Lung Cancer Articles Published in 2020 and 2021

[SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1- \$\gamma\$ , and Point Mutation in the Transcription Intermediary Factor 1- \$\gamma\$  Coding Gene: A Case Report](#) by Arnon, Johnathan et al. JTO Clinical and Research Reports, Volume 2, Issue 9, 100217

[Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study](#) by Akamatsu, Hiroaki et al. JTO Clinical and Research Reports, Volume 2, Issue 7, 100184

[Salvage Surgery for Patients With Local Recurrence or Persistent Disease After Treatment With Chemoradiotherapy for SCLC](#) by Joosten, Pieter J.M. et al. JTO Clinical and Research Reports, Volume 2, Issue 5, 100172

[Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy](#) by Chen, Hui-Zi et al. JTO Clinical and Research Reports, Volume 2, Issue 4, 100164

[Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors](#) by Kareff, Samuel A. et al. JTO Clinical and Research Reports, Volume 2, Issue 4, 100149

[Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC](#) by Smith, Jarrod T. et al. JTO Clinical and Research Reports, Volume 2, Issue 3, 100110

[Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC](#) by Tapan, Umit et al. JTO Clinical and Research Reports, Volume 2, Issue 1, 100109

[Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib](#) by Batra, Ullas et al. JTO Clinical and Research Reports, Volume 2, Issue 1, 100098

[Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC](#) by Ricciuti, Biagio et al. JTO Clinical and Research Reports, Volume 1, Issue 4, 100074

[Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease](#) by Iams, Wade T. et al. JTO Clinical and Research Reports, Volume 1, Issue 2, 100024

[Development and Validation of a Simplified Prognostic Score in SCLC](#) by Negre, Elodie et al. JTO Clinical and Research Reports, Volume 1, Issue 1, 100016

For more information, contact [journals@iaslc.org](mailto:journals@iaslc.org)